





Gabriela Guillena and Carmen Nájera*

Tetrahedron: Asymmetry 12 (2001) 181

Ee = 100%

 $[\alpha]_D^{25} = +146.2$ (*c* 1.9, CHCl₃)

Source of chirality: (+)-Pseudoephedrine

Absolute configuration: (1*S*,2*S*)(1*S*,2*S*)-*N*-(2-Hydroxy-1-methyl-2-phenethyl)-2'-(dimethylsulfanylmethylene)-amino-*N*-methylacetamideAntonio García Martínez,* Enrique Teso Vilar, Amelia García Fraile,
Santiago de la Moya Cerero* and Beatriz Lora Maroto*Tetrahedron: Asymmetry* 12 (2001) 189 $C_{10}H_{13}NO_2$
(1*R*)- α,α -Dimethyl-3-cyanocyclopent-2-eneacetic acid $[\alpha]_D^{20} = +69.6$ (*c* 1.40, CH₂Cl₂)Source of chirality: (1*R*)-3-*endo*-bromocamphor
and stereospecific synthesisAbsolute configuration: *R*Antonio García Martínez,* Enrique Teso Vilar, Amelia García Fraile,
Santiago de la Moya Cerero* and Beatriz Lora Maroto*Tetrahedron: Asymmetry* 12 (2001) 189 $C_{10}H_{14}O_4$
(1*R*)- α,α -Dimethyl-3-carboxycyclopent-2-eneacetic acid $[\alpha]_D^{20} = +30.1$ (*c* 1.84, CH₂Cl₂)Source of chirality: (1*R*)-3-*endo*-bromocamphor
and stereospecific synthesisAbsolute configuration: *R*


Robert K. Boeckman, Jr.,* Michelle A. Laci and Alan T. Johnson


Tetrahedron: Asymmetry 12 (2001) 205

Ee = 100%

 $[\alpha]_D^{23} - 284.3$ (*c* 1.8, CH₂Cl₂)

Source of chirality: camphoric acid

Absolute configuration: 1*S*,4*R*(1*S*,4*R*)-4,7,7-Trimethyl-2-azabicyclo[2.2.1]-5-hepten-3-one




(*S*)-2-Amino-2-phenylacetonitrile

Ee = 97%

$[\alpha]_D = -27.5$ (*c* 1, CH₂Cl₂)

Source of chirality: crystallisation with tartaric acid

Absolute configuration: *S*




(*R*)-2-Amino-3,3-dimethylpropionitrile

Ee = 97%

$[\alpha]_D = +13.3$ (*c* 1, CH₂Cl₂)

Source of chirality: crystallisation with tartaric acid

Absolute configuration: *R*




(*R*)-2-Amino-4-phenylbutyronitrile

Ee = 98%

$[\alpha]_D = -11.5$ (*c* 1, CH₂Cl₂)

Source of chirality: crystallisation with tartaric acid

Absolute configuration: *R*




(*S*)-3-Hydroxy-2,2-dimethylcyclohexanone

Ee = >96%

$[\alpha]_D^{25} = +22.5$ (*c* 2.0, CHCl₃)

Source of chirality: microbial transformation

Absolute configuration: *S*




(S)-3-Hydroxy-2,2-di(prop-2-ynyl)cyclohexanone

Ee = >96%

 $[\alpha]_D^{20} = -3.5$ (*c* 2.0, CHCl₃)

Source of chirality: microbial transformation


Absolute configuration: *S*

(S)-2,2-Diallyl-3-hydroxycyclohexanone

Ee = 98.4%

 $[\alpha]_D^{20} = +11$ (*c* 2.2, CHCl₃)

Source of chirality: microbial transformation


Absolute configuration: *S*


(S)-2,2-Diallyl-3-oxocyclohexanol 3-(+)-camphorsulfonate

Ee = 98.4%

 $[\alpha]_D^{20} = +43.6$ (*c* 0.2, CHCl₃)


Source of chirality: microbial transformation

Absolute configuration: *S,S* $C_{18}H_{20}N_2O_2$ (3*R*,7*R*,4*aR*,8*aR*)-3,7-*cis*-Perhydro-[1,4]oxazino-[3,2-*b*]-1,4-oxazine $[\alpha]_D^{25} = -164.6$ (*c* = 0.1, CH₂Cl₂)Source of chirality: (*R*)-(−)-phenylglycinolAbsolute configuration: (3*R*,7*R*,4*aR*,8*aR*)




C₂₀H₂₂N₂O₂
(2R,2'R,4R,4'R)-N,N'-Ethylene(4,4'-diphenyl)-2,2'-bisoxazolidine

[α]_D²⁵ = -245.79 (*c* = 0.107, CH₂Cl₂)
Source of chirality: (R)-(-)-phenylglycinol
Absolute configuration: (2*R*,2'*R*,4*R*,4'*R*)




C₂₇H₂₈N₂O₂
(2*R*,2'*S*,4*R*,4'*R*)-N,N'-Ethylene(2'-methyl-2,4,4'-triphenyl)-2,2'-bisoxazolidine

[α]_D²⁵ = -145 (*c* = 0.94, CH₂Cl₂)
Source of chirality: (R)-(-)-phenylglycinol
Absolute configuration: (2*R*,2'*S*,4*R*,4'*R*)




C₂₀H₂₆N₂O₂
(1'*R*)-1,4-Bis-[(2'-hydroxy-1'-phenyl)ethyl]piperazine

[α]_D²⁵ = 21.77 (*c* = 0.107, CH₂Cl₂)
Source of chirality: (R)-(-)-phenylglycinol
Absolute configuration: (1'*R*)



C₂₂H₃₀N₂O₂
(1'*R*,2*S*)-1,4-Bis-[(2'-hydroxy-1'-phenyl)ethyl]-2,3-dimethylpiperazine

[α]_D²⁵ = -28.2 (*c* = 0.156, CHCl₃)
Source of chirality: (R)-(-)-phenylglycinol
Absolute configuration: (1'*R*,2*S*)




$C_{22}H_{30}N_2O_2$
(1'R,2R)-1,4-Bis-[{(2'-hydroxy-1'-phenyl)ethyl]-2,3-dimethylpiperazine}

$[\alpha]_D^{25} = -47.17$ ($c = 0.106$, CHCl₃)

Source of chirality: (R)-(-)-phenylglycinol

Absolute configuration: (1'R,2R)




$C_{27}H_{32}N_2O_2$
(1'R,2S,3R)-1,4-Bis-[{(2'-hydroxy-1'-phenyl)ethyl]-2-phenyl-3-methyl-piperazine

$[\alpha]_D^{25} = -81.1$ ($c = 0.172$, CHCl₃)

Source of chirality: (R)-(-)-phenylglycinol

Absolute configuration: (1'R,2S,3R)




$C_{12}H_{16}N_2O_4$
(R)-O-MOM-Mandelic-Gly-NH₂

Ee >99%

$[\alpha]_D^{26} = -57.6$ (c 1.54, MeOH)

Source of chirality: natural

Absolute configuration: R




$C_{11}H_{14}N_2O_3$
(R)-Phenyllactic-Gly-NH₂

Ee >99%

$[\alpha]_D^{26} = -72.9$ (c 0.23, MeOH)


Source of chirality: natural

Absolute configuration: R




C₁₂H₁₆N₂O₄
(S)-O-MOM-Mandelic-Gly-NH₂

Ee >99%
[α]_D²⁴ = +56.7 (c 1.78, MeOH)
Source of chirality: natural
Absolute configuration: S




C₁₇H₁₈N₂O₃
(S)-O-Bn-Mandelic-Gly-NH₂

Ee >99%
[α]_D²⁴ = +6.8 (c 0.78, MeOH)
Source of chirality: natural
Absolute configuration: S




C₁₂H₁₆N₂O₃
(R)-Phenyllactic-D-Ala-NH₂

Ee >99%
[α]_D²⁷ = +54.0 (c 0.71, MeOH)
Source of chirality: natural
Absolute configuration: R,R




C₁₇H₁₈N₂O₃
(R)-O-Bn-Mandelic-Gly-NH₂

Ee >99%
[α]_D²⁴ = -6.1 (c 1.29, MeOH)
Source of chirality: natural
Absolute configuration: R




C₁₂H₁₆N₂O₃
(S)-Phenyllactic-Ala-NH₂

Ee >99%
[α]_D²⁷ = -55.1 (c 1.65, MeOH)
Source of chirality: natural
Absolute configuration: S,S




C₁₂H₁₆N₂O₃
(R)-Phenyllactic-L-Ala-NH₂

Ee >99%
[α]_D²⁷ = +52.6 (c 1.25, MeOH)
Source of chirality: natural
Absolute configuration: R,S



C₁₂H₁₆N₂O₃
(S)-Phenyllactic-D-Ala-NH₂


Ee >99%
[α]_D²⁷ = -52.5 (c 1.19, MeOH)
Source of chirality: natural
Absolute configuration: S,R



C₁₇H₂₅N₃O₄

(R)-3-[(t-Butyloxycarbonyl)amino]-2-benzylpropanoic-Gly-NH₂

Ee >99%
[α]_D²⁶ = +2.9 (c 0.70, MeOH)
Source of chirality: enzymatic enantiotropic differentiation
Absolute configuration: R




Ee >99%


$[\alpha]_D^{25} = -3.8$ (*c* 0.16, MeOH)

Source of chirality: enzymatic enantiotropic differentiation

Absolute configuration: *S*



(*S*)-3-[(*t*-Butyloxycarbonyl)amino]-2-benzylpropanoic-Gly-NH₂



Ee >99%


$[\alpha]_D^{24} = -11.3$ (*c* 0.46, MeOH)

Source of chirality: enzymatic, natural

Absolute configuration: *S,S*



(*S*)-3-[(*t*-Butyloxycarbonyl)amino]-2-benzylpropanoic-L-Ala-NH₂



Ee >99%


$[\alpha]_D^{24} = +9.7$ (*c* 0.64, MeOH)

Source of chirality: enzymatic, natural

Absolute configuration: *R,S*



(*R*)-3-[(*t*-Butyloxycarbonyl)amino]-2-benzylpropanoic-L-Ala-NH₂



Ee >99%


$[\alpha]_D^{26} = +72.1$ (*c* 0.19, MeOH)

Source of chirality: natural

Absolute configuration: *S*



(*S*)-Phenyllactic-Gly-NH₂



Ee >99%


$[\alpha]_D^{24} = -9.4$ (*c* 0.47, MeOH)

Source of chirality: enzymatic, natural

Absolute configuration: *S,R*



(*S*)-3-[(*t*-Butyloxycarbonyl)amino]-2-benzylpropanoic-d-Ala-NH₂



Ee >99%


$[\alpha]_D^{24} = +11.7$ (*c* 1.33, MeOH)

Source of chirality: enzymatic, natural

Absolute configuration: *R,R*



(*R*)-3-[(*t*-Butyloxycarbonyl)amino]-2-benzylpropanoic-d-Ala-NH₂




Ee = >98%

$[\alpha]_D^{19} = -78.3$ (*c* 0.95, CHCl₃)

Source of chirality: diastereomeric resolution

Absolute configuration: *S_{ax}*

(*S_{ax}*)-2,2'-Bis(di-2-furylphosphino)-1,1'-binaphthalene



Ee = 93.0% [by NMR in the presence of (-)-ephedrine]


$[\alpha]_D^{25} = +9.54$ (*c* 2, EtOH)

Source of chirality: enzymatic asymmetric

Absolute configuration: *R*

(assigned by chemical correlation)

(*R*)-2-Benzoyloxy-2-methylmalonic acid monoethyl ester



(*R*)-2-Benzyl-2-methylmalonic acid monomethyl ester


Ee = 89.0% [by NMR in the presence of (-)-ephedrine]

$[\alpha]_D^{25} = +5.27$ (*c* 2.1, CHCl₃)

Source of chirality: enzymatic asymmetrication

Absolute configuration: *R*

(assigned by $[\alpha]_D$ and NMR analogy with the corresponding monoethyl ester)



(*S*)-2-Benzyl-2-methylmalonic acid ethyl ester phenyl ester


Ee = 93.0% [by NMR in the presence of Eu(hfc)₃]

$[\alpha]_D^{25} = +9.46$ (*c* 1.65, CHCl₃)

Source of chirality: enzymatic asymmetrication

Absolute configuration: *S*

(assigned by chemical correlation)



(*S*)-2-Hydroxy-2-methylmalonic acid ethyl ester phenyl ester


Ee = 93.0% [by NMR in the presence of Eu(hfc)₃]

$[\alpha]_D^{25} = -0.45$ (*c* 2.1, CHCl₃)

Source of chirality: enzymatic asymmetrication

Absolute configuration: *S*

(assigned by chemical correlation)



(*R*)-3-(3,5-Dichlorophenyl)-5-methyl-2,4-dioxooxazolidine-5-carboxylic acid ethyl ester


Ee >96.0% [by NMR in the presence of Eu(hfc)₃]

$[\alpha]_D^{25} = -16.79$ (*c* 2.0, CHCl₃)

Source of chirality: enzymatic asymmetrication

Absolute configuration: *R*

(assigned by chemical correlation)




C_8H_8FNO
(*R*)-2-Fluoro-2-phenylacetamide

Ee = >99%

 $[\alpha]_D^{20} = +122.3$ (*c* 0.90, CHCl₃)

Source of chirality: nitrilase catalysed kinetic resolution of the respective 2-fluoroethanenitrile


Absolute configuration: 2*R*

$C_9H_{10}FNO$
(*R*)-2-Fluoro-2-(3-methylphenyl)acetamide

Ee = 97%

 $[\alpha]_D^{20} = +107.3$ (*c* 0.70, CHCl₃)

Source of chirality: nitrilase catalysed kinetic resolution of the respective 2-fluoroethanenitrile


Absolute configuration: 2*R*

$C_9H_{10}FNO_2$
(*R*)-2-Fluoro-2-(3-methoxyphenyl)acetamide

Ee = >99%

 $[\alpha]_D^{20} = +141.8$ (*c* 1.00, CHCl₃)

Source of chirality: nitrilase catalysed kinetic resolution of the respective 2-fluoroethanenitrile

Absolute configuration: 2*R*


$C_8H_7FO_2$
(*R*)-2-Fluoro-2-phenylacetic acid

Ee = >99%

 $[\alpha]_D^{20} = +150.3$ (*c* 1.00, CHCl₃)

Source of chirality: hydrolysis of the respective 2-fluoroacetamide

Absolute configuration: 2*R*




$C_9H_9FO_2$
(*R*)-2-Fluoro-2-(3-methylphenyl)acetic acid

Ee = 98%

 $[\alpha]_D^{20} = +137.4$ (*c* 1.00, CHCl₃)

Source of chirality: hydrolysis of the respective 2-fluoroacetamide


Absolute configuration: 2*R*

$C_9H_9FO_3$
(*R*)-2-Fluoro-2-(3-methoxyphenyl)acetic acid

Ee = >99%


 $[\alpha]_D^{20} = +154.0$ (*c* 1.00, CHCl₃)

Source of chirality: hydrolysis of the respective 2-fluoroacetamide

Absolute configuration: 2*R*

$C_{29}H_{28}NO_2P$
(*S*)-*N*-(1-Benzyl-2-methoxyethyl)-2-(diphenylphosphino)benzamide


Ee = >95%

 $[\alpha]_D^{20} = -14.5$ (*c* 0.80, CHCl₃)Source of chirality: (*S*)-(+)2-amino-1-methoxy-3-phenylpropaneAbsolute configuration: *S*

$C_{21}H_{21}NO_3$
(*S*)-*N*-(1-Benzyl-2-methoxyethyl)-2-hydroxynaphthalenecarboxamide


Ee = >95%

 $[\alpha]_D^{25} = -54.4$ (*c* 0.16, CHCl₃)Source of chirality: (*S*)-(+)2-amino-1-methoxy-3-phenylpropaneAbsolute configuration: *S*




$C_{22}H_{20}F_3NO_5S$
(*S*)-*N*-(1-Benzyl-2-methoxyethyl)-2-(trifluoromethanesulfonyloxy)naphthalenecarboxamide

Ee = >95%

 $[\alpha]_D^{25} = -23.7$ (*c* 0.35, CHCl₃)Source of chirality: (*S*)-(+)2-amino-1-methoxy-3-phenylpropaneAbsolute configuration: *S*

$C_{33}H_{30}NO_2P$
(*S*)-*N*-(1-Benzyl-2-methoxyethyl)-2-(diphenylphosphino)naphthalenecarboxamide

Ee = >95%

 $[\alpha]_D^{25} = -18.7$ (*c* 0.17, CHCl₃)Source of chirality: (*S*)-(+)2-amino-1-methoxy-3-phenylpropaneAbsolute configuration: *S*


$C_8H_{18}O_4$
(*S*)-3-*O*-(2-Methoxyethoxymethyl)-1,3-butanediol

 $[\alpha]_D = +96$ (*c* 1.3, chloroform)

Source of chirality: chemoenzymatic resolution

Absolute configuration: *S*

(assigned by chemical correlation)




$C_{30}H_{30}O_2$
(*R*)-3-*O*-Benzyl-1-*O*-trityl-1,3-butanediol

 $[\alpha]_D = -8$ (*c* 1, chloroform)

Source of chirality: chemoenzymatic resolution

Absolute configuration: *R*

(assigned by chemical correlation)




Methyl (S)-8-O-(2-methoxyethoxymethyl)-4-oxononanoate

[α]_D = +11 (*c* 1.7, chloroform)

Source of chirality: chemoenzymatic resolution

Absolute configuration: *S*
(assigned by chemical correlation)




Methyl (R)-8-benzyloxy-4-oxononanoate

[α]_D = -16 (*c* 1, chloroform)

Source of chirality: chemoenzymatic resolution

Absolute configuration: *R*
(assigned by chemical correlation)




(5*S*,7*S*)-7-Methyl-1,6-dioxaspiro[4.5]decane

Ee = 91%

[α]_D = -87 (*c* 1, *n*-pentane)

Source of chirality: chemoenzymatic resolution

Absolute configuration: (5*S*,7*S*)
(assigned by comparison with literature data
and chemical correlation)



(1*S*,5*R*,6*S*,9*R*)-1,5,6,9-Tetramethylbicyclo[4.3.0]nonan-3-one

Ee = 99.5%


[α]_D²⁵ = -22.6 (*c* 0.15, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: (1*S*,5*R*,6*S*,9*R*)

Motoo Tori,* Chiho Makino, Kenji Hisazumi, Masakazu Sono
and Katsuyuki Nakashima

Tetrahedron: Asymmetry 12 (2001) 301



C₁₄H₂₂O

(1*S*,5*R*,6*S*,9*S*)-1,5,6-Trimethyl-9-vinylbicyclo[4.3.0]nonan-3-one

Ee = 99.5%


[α]_D²⁰ = -18.0 (*c* 1.18, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: (1*S*,5*R*,6*S*,9*S*)

Motoo Tori,* Chiho Makino, Kenji Hisazumi, Masakazu Sono
and Katsuyuki Nakashima

Tetrahedron: Asymmetry 12 (2001) 301



C₁₇H₃₀OSi

(4*S*,5*R*)-3,4,5-Trimethyl-4-[3'*Z*-5'-trimethylsilyl-3'-pentenyl]cyclohex-2-en-1-one

Ee = 99.5%


[α]_D²¹ = +8.9 (*c* 0.66, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: (4*S*,5*R*)

Motoo Tori,* Chiho Makino, Kenji Hisazumi, Masakazu Sono
and Katsuyuki Nakashima

Tetrahedron: Asymmetry 12 (2001) 301



C₁₇H₃₂Si

(3*S*,4*R*)-2,3,4-Trimethyl-3-[3'*Z*-5'-trimethylsilyl-3'-pentenyl]cyclohexene

Ee = 99.5%


[α]_D²¹ = +43.0 (*c* 0.86, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: (3*S*,4*R*)

Yasushi Kawai,* Yoshikazu Inaba and Norihiro Tokitoh

Tetrahedron: Asymmetry 12 (2001) 309



C₁₀H₁₃NO₂


(2*R*,3*R*)-3-Phenyl-2-nitrobutane

Ee = 98%

[α]_D = +8.5 (*c* 1.0, EtOH)

Source of chirality: microbial reduction

Absolute configuration: (2*R*,3*R*)





(2S,3R)-3-Phenyl-2-nitrobutane

Ee = 97%

[α]_D = +91.5 (*c* 1.0, EtOH)

Source of chirality: microbial reduction

Absolute configuration: (2S,3R)




(2R,3R)-3-(3'-Chlorophenyl)-2-nitrobutane

Ee = 82%

[α]_D = +7.5 (*c* 1.0, EtOH)

Source of chirality: microbial reduction

Absolute configuration: (2R,3R)




(2S,3R)-3-(3'-Chlorophenyl)-2-nitrobutane

Ee = 81%

[α]_D = +54.8 (*c* 0.90, EtOH)

Source of chirality: microbial reduction

Absolute configuration: (2S,3R)




(2R,3R)-3-(4'-Chlorophenyl)-2-nitrobutane

Ee = 94%

[α]_D = +8.2 (*c* 1.0, EtOH)

Source of chirality: microbial reduction

Absolute configuration: (2R,3R)





(2S,3R)-3-(4'-Chlorophenyl)-2-nitrobutane

Ee = 92%

$[\alpha]_D^{25} = +82.6$ (*c* 1.0, EtOH)

Source of chirality: microbial reduction


Absolute configuration: (2S,3R)

(-)-(1R,2R)-1,2-Diaminocyclohexane-*n*-propylurea

$[\alpha]_D^{22} = -1.7$ (*c* = 5, CHCl₃)

Source of chirality: (1R,2R)-1,2-diaminocyclohexane obtained by optical resolution


Absolute configuration: (1R,2R)




$[\alpha]_D^{22} = -2.4$ (*c* = 5, CHCl₃)

Source of chirality: (1R,2R)-1,2-diaminocyclohexane obtained by optical resolution

Absolute configuration: (1R,2R)




(-)-(1R,2R)-1,2-Diaminocyclohexane-cyclohexylurea




$[\alpha]_D^{22} = -5.8$ (*c* = 5, CHCl₃)


Source of chirality: (1R,2R)-1,2-diaminocyclohexane obtained by optical resolution

Absolute configuration: (1R,2R)


(-)-(1R,2R)-1,2-Diaminocyclohexane-*tert*-butylurea


 $[\alpha]_D^{22} = -19.5$ ($c = 5$, CHCl₃)


 Source of chirality: (1*R*,2*R*)-1,2-diaminocyclohexane obtained by optical resolution

 Absolute configuration: (1*R*,2*R*)
(-)-(1*R*,2*R*)-1,2-Diaminocyclohexane-phenylurea
 $[\alpha]_D^{22} = -3.6$ ($c = 5$, CHCl₃)

 Source of chirality: (1*R*,2*R*)-1,2-diaminocyclohexane obtained by optical resolution


 Absolute configuration: (1*R*,2*R*)
(-)-(1*R*,2*R*)-1,2-Diaminocyclohexane-4-methoxyphenylurea
 $[\alpha]_D^{22} = -4.7$ ($c = 5$, CHCl₃)

 Source of chirality: (1*R*,2*R*)-1,2-diaminocyclohexane obtained by optical resolution

 Absolute configuration: (1*R*,2*R*)
(-)-(1*R*,2*R*)-1,2-Diaminocyclohexane-2-tolylurea
 $[\alpha]_D^{22} = -5.2$ ($c = 5$, CHCl₃)

 Source of chirality: (1*R*,2*R*)-1,2-diaminocyclohexane obtained by optical resolution

 Absolute configuration: (1*R*,2*R*)
(-)-(1*R*,2*R*)-1,2-Diaminocyclohexane-4-trifluoromethylphenylurea




$C_{17}H_{21}N_3O$
 $(-)-(1R,2R)$ -1,2-Diaminocyclohexane-1-naphthylurea

$[\alpha]_D^{22} = -2.9$ ($c = 2$, $CHCl_3$)

Source of chirality: (1*R*,2*R*)-1,2-diaminocyclohexane obtained by optical resolution

Absolute configuration: (1*R*,2*R*)




$C_{20}H_{36}N_4O_2$
 $(+)-(1R,2R)$ -1,2-Diaminocyclohexane-cyclohexyldiurea

$[\alpha]_D^{22} = +0.28$ ($c = 1$, $CHCl_3/EtOH$ 1:1)

Source of chirality: (1*R*,2*R*)-1,2-diaminocyclohexane obtained by optical resolution

Absolute configuration: (1*R*,2*R*)




$C_{11}H_{23}N_3S$
 $(+)-(1R,2R)$ -1,2-Diaminocyclohexane-*n*-butylthiourea

$[\alpha]_D^{22} = +5.3$ ($c = 5$, $CHCl_3$)

Source of chirality: (1*R*,2*R*)-1,2-diaminocyclohexane obtained by optical resolution

Absolute configuration: (1*R*,2*R*)




$C_{11}H_{23}N_3S$
 $(+)-(1R,2R)$ -1,2-Diaminocyclohexane-*tert*-butylthiourea

$[\alpha]_D^{22} = +6.5$ ($c = 5$, $CHCl_3$)

Source of chirality: (1*R*,2*R*)-1,2-diaminocyclohexane obtained by optical resolution

Absolute configuration: (1*R*,2*R*)




$C_{13}H_{25}N_3S$
(+)-(1*R*,2*R*)-1,2-Diaminocyclohexane-cyclohexylthiourea

$[\alpha]_D^{22} = +7.5$ ($c = 5$, CHCl₃)

Source of chirality: (1*R*,2*R*)-1,2-diaminocyclohexane obtained by optical resolution

Absolute configuration: (1*R*,2*R*)




$C_{12}H_{13}NOS$
(5*S*)-2-Benzylthio-5-vinyl- Δ^2 -1,3-oxazoline

$[\alpha]_D = -13$ (c 1, CHCl₃)

Source of chirality: natural

Absolute configuration: 5*S*




$C_{16}H_{15}NOS$
(5*R*)-2-Benzylthio-5-phenyl- Δ^2 -1,3-oxazoline

$[\alpha]_D = +180$ (c 1, CHCl₃)

Source of chirality: natural

Absolute configuration: 5*R*




$C_{11}H_{13}NOS$
(4*R*)-2-Benzylthio-4-methyl- Δ^2 -1,3-oxazoline


$[\alpha]_D = +8$ (c 0.4, CHCl₃)

Source of chirality: natural


Absolute configuration: 4*R*

(5*S*)-2-Benzylthio-5-ethyl-5-methyl- Δ^2 -1,3-oxazoline $[\alpha]_D = -9$ (*c* 2.9, CHCl₃)


Source of chirality: natural

Absolute configuration: 5*S*(2*S*)-2-Vinyl-2,3-dihydro-5*H*-[1,3]oxazolo[2,3-*b*]quinazolin-5-one $[\alpha]_D = -60$ (*c* 1.0, CHCl₃)

Source of chirality: natural


Absolute configuration: 2*S*(2*R*)-2-Phenyl-2,3-dihydro-5*H*-[1,3]oxazolo[2,3-*b*]quinazolin-5-one $[\alpha]_D = +79$ (*c* 1.0, CHCl₃)

Source of chirality: natural

Absolute configuration: 2*R*(3*R*)-3-Methyl-2,3-dihydro-5*H*-[1,3]oxazolo[2,3-*b*]quinazolin-5-one $[\alpha]_D = -105$ (*c* 1.0, CHCl₃)

Source of chirality: natural


Absolute configuration: 3*R*

 $C_{13}H_{14}N_2O_2$ (2S)-2-Ethyl-2-methyl-2,3-dihydro-5*H*-[1,3]oxazolo[2,3-*b*]quinazolin-5-one $[\alpha]_D = -15$ (*c* 1.0, CHCl₃)


Source of chirality: natural

Absolute configuration: 2*S* $C_{12}H_9ClN_2O_2$ (2*R*)-8-Chloro-2-vinyl-2,3-dihydro-5*H*-[1,3]oxazolo[2,3-*b*]quinazolin-5-one $[\alpha]_D = +48$ (*c* 1.0, CHCl₃)

Source of chirality: natural

Absolute configuration: 2*R* $C_{13}H_{12}N_2O_2$ (2*R*)-7-Methyl-2-vinyl-2,3-dihydro-5*H*-[1,3]oxazolo[2,3-*b*]quinazolin-5-one $[\alpha]_D = +64$ (*c* 1.0, CHCl₃)

Source of chirality: natural



Absolute configuration: 2*R* $C_{19}H_{21}NO_4S$ Ethyl (S)-2-methyl-4-(2-ethylsulfanyl-phenyl)-5-oxo-1,4,5,7-tetrahydrofuro[3,4-*b*]pyridine-3-carboxylate

Ee = 99%

 $[\alpha]_D^{20} = -73.1$ (*c* = 0.75, DMSO)

Source of chirality: resolution by chiral HPLC

Absolute configuration: *S*





Ethyl (S)-2-methyl-4-[2-(2-phenylethyl)phenyl]-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridine-3-carboxylate

Ee = 99%

 $[\alpha]_D^{20} = -72.5$ ($c = 0.91$, MeOH)

Source of chirality: resolution by chiral HPLC

Absolute configuration: S





Ethyl (S)-2-methyl-4-(2-propylphenyl)-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridine-3-carboxylate

Ee = 99%

 $[\alpha]_D^{20} = -131.9$ ($c = 0.91$, DMSO)

Source of chirality: resolution by chiral HPLC

Absolute configuration: S




'Propyl (R)-2-methyl-4-(2-methylphenyl)-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridine-3-carboxylate

Ee = 99%

 $[\alpha]_D^{20} = -133.9$ ($c = 0.75$, MeOH)

Source of chirality: resolution by chiral HPLC

Absolute configuration: R




Ethyl (S)-4-(2-ethylsulfanyl-phenyl)-2-methyl-5-oxo-5,7-dihydrofuro[3,4-b]pyridine-3-carboxylate

Ee = 93%

 $[\alpha]_D^{20} = +118.6$ ($c = 1.2$, MeOH)

Source of chirality: chirality transfer

Absolute configuration: S




Ee = 96%


 $[\alpha]_D^{20} = +17.8$ ($c = 1.0$, MeOH)

Source of chirality: chirality transfer

Absolute configuration: S



Ethyl (S)-2-methyl-5-oxo-4-[2-(2-phenylethyl)phenyl]-5,7-dihydrofuro[3,4-b]pyridine-3-carboxylate




Ee = 93%


 $[\alpha]_D^{20} = +63.4$ ($c = 0.9$, MeOH)

Source of chirality: chirality transfer

Absolute configuration: S



Ethyl (S)-2-methyl-5-oxo-4-(2-propylphenyl)-5,7-dihydrofuro[3,4-b]pyridine-3-carboxylate



Ee = 97%


 $[\alpha]_D^{20} = +99.3$ ($c = 1.1$, MeOH)

Source of chirality: chirality transfer

Absolute configuration: R



'Propyl (R)-2-methyl-5-oxo-4-(2-methylphenyl)-5,7-dihydrofuro[3,4-b]pyridine-3-carboxylate




E.e. = 100%


 $[\alpha]_D^{23} = +90.3$ ($c = 1.1$, CHCl₃)

Source of chirality: L-alanine and asymmetric synthesis

Absolute configuration: (2R,3S)



(2R,3S)-3-(N,N-Dibenzylamino)-2-hydroxybutanenitrile




C₁₈H₂₀N₂O
(2S,3S)-3-(N,N-Dibenzylamino)-2-hydroxybutanenitrile

E.e. = 100%

[α]_D²³ = +24.7 (*c* = 0.9, CHCl₃)

Source of chirality: L-alanine and asymmetric synthesis

Absolute configuration: (2S,3S)




C₂₀H₂₄N₂O
(2R,3S)-3-(N,N-Dibenzylamino)-2-hydroxy-4-methylpentanenitrile

E.e. = 100%

[α]_D²³ = +15.8 (*c* = 1.2, CHCl₃)

Source of chirality: L-valine and asymmetric synthesis

Absolute configuration: (2R,3S)




C₂₀H₂₄N₂O
(2S,3S)-3-(N,N-Dibenzylamino)-2-hydroxy-4-methylpentanenitrile

E.e. = 100%

[α]_D²³ = -49.5 (*c* = 1.0, CHCl₃)

Source of chirality: L-valine and asymmetric synthesis

Absolute configuration: (2S,3S)




C₂₁H₂₆N₂O
(2R,3S)-3-(N,N-Dibenzylamino)-2-hydroxy-5-methylhexanenitrile

E.e. = 100%

[α]_D²³ = +45.5 (*c* = 1.1, CHCl₃)

Source of chirality: L-leucine and asymmetric synthesis

Absolute configuration: (2R,3S)




C₂₁H₂₆N₂O
(2S,3S)-3-(N,N-Dibenzylamino)-2-hydroxy-5-methylhexanenitrile

E.e. = 100%

[α]_D²³ = +23.3 (*c* = 1.0, CHCl₃)

Source of chirality: L-leucine and asymmetric synthesis

Absolute configuration: (2S,3S)




C₂₄H₂₄N₂O
(2R,3S)-3-(N,N-Dibenzylamino)-2-hydroxy-4-phenylbutanenitrile

E.e. = 100%

[α]_D²³ = +46.8 (*c* = 1.0, CHCl₃)

Source of chirality: L-phenylalanine and asymmetric synthesis

Absolute configuration: (2R,3S)




C₂₄H₂₄N₂O
(2S,3S)-3-(N,N-Dibenzylamino)-2-hydroxy-4-phenylbutanenitrile

E.e. = 100%

[α]_D²³ = +48.0 (*c* = 1.0, CHCl₃)

Source of chirality: L-phenylalanine and asymmetric synthesis

Absolute configuration: (2S,3S)




C₂₃H₂₂N₂O
(2S,3R)-3-(N,N-Dibenzylamino)-2-hydroxy-3-phenylpropanenitrile

E.e. = 100%

[α]_D²³ = -139.7 (*c* = 1.0, CHCl₃)

Source of chirality: D-2-phenylglycine and asymmetric synthesis

Absolute configuration: (2S,3R)




C₂₃H₂₂N₂O
(2R,3R)-3-(*N,N*-Dibenzylamino)-2-hydroxy-3-phenylpropanenitrile

E.e. = 100%

[α]_D²³ = -81.6 (*c* = 1.1, CHCl₃)

Source of chirality: D-2-phenylglycine and asymmetric synthesis

Absolute configuration: (2*R*,3*R*)




C₂₂H₂₈N₂O₄
(2*R*,3*S*)-3-(*N,N*-Dibenzylamino)-2-hydroxy-4-[(2-methoxyethoxy)methoxy]butanenitrile

E.e. = 100%

[α]_D²³ = +9.8 (*c* = 1.2, CHCl₃)

Source of chirality: L-serine and asymmetric synthesis

Absolute configuration: (2*R*,3*S*)




C₂₂H₂₈N₂O₄
(2*S*,3*S*)-3-(*N,N*-Dibenzylamino)-2-hydroxy-4-[(2-methoxyethoxy)methoxy]butanenitrile

E.e. = 100%

[α]_D²³ = +24.2 (*c* = 0.6, CHCl₃)

Source of chirality: L-serine and asymmetric synthesis

Absolute configuration: (2*S*,3*S*)




C₁₈H₂₁NO₃
(2*R*,3*S*)-3-(*N,N*-Dibenzylamino)-2-hydroxybutanoic acid

E.e. = 100%

[α]_D²³ = +66.0 (*c* = 1.1, CHCl₃)

Source of chirality: L-alanine and asymmetric synthesis

Absolute configuration: (2*R*,3*S*)




C₁₈H₂₁NO₃
(2S,3S)-3-(N,N-Dibenzylamino)-2-hydroxybutanoic acid

E.e. = 100%

[α]_D²³ = +40.2 (*c* = 1.0, CHCl₃)

Source of chirality: L-alanine and asymmetric synthesis
Absolute configuration: (2S,3S)




C₂₁H₂₇NO₃
(2R,3S)-3-(N,N-Dibenzylamino)-2-hydroxy-5-methylhexanoic acid

E.e. = 100%

[α]_D²³ = +60.3 (*c* = 1.1, CHCl₃)

Source of chirality: L-leucine and asymmetric synthesis
Absolute configuration: (2R,3S)




C₂₁H₂₇NO₃
(2S,3S)-3-(N,N-Dibenzylamino)-2-hydroxy-5-methylhexanoic acid

E.e. = 100%

[α]_D²³ = +33.8 (*c* = 0.9, CHCl₃)

Source of chirality: L-leucine and asymmetric synthesis
Absolute configuration: (2S,3S)




C₂₄H₂₅NO₃
(2R,3S)-3-(N,N-Dibenzylamino)-2-hydroxy-4-phenylbutanoic acid

E.e. = 100%

[α]_D²³ = +33.4 (*c* = 1.0, CHCl₃)

Source of chirality: L-phenylalanine and asymmetric synthesis
Absolute configuration: (2R,3S)



C₂₄H₂₅NO₃


(2S,3S)-3-(N,N-Dibenzylamino)-2-hydroxy-4-phenylbutanoic acid

E.e. = 100%

[α]_D²³ = +49.9 (*c* = 1.1, CHCl₃)

Source of chirality: L-phenylalanine and asymmetric synthesis

Absolute configuration: (2S,3S)



C₂₃H₂₃NO₃


(2S,3R)-3-(N,N-Dibenzylamino)-2-hydroxy-3-phenylpropanoic acid

E.e. = 100%

[α]_D²³ = -83.0 (*c* = 1.0, CHCl₃)

Source of chirality: D-2-phenylglycine and asymmetric synthesis

Absolute configuration: (2S,3R)



C₂₃H₂₃NO₃


(2R,3R)-3-(N,N-Dibenzylamino)-2-hydroxy-3-phenylpropanoic acid

E.e. = 100%

[α]_D²³ = -77.0 (*c* = 1.1, CHCl₃)

Source of chirality: D-2-phenylglycine and asymmetric synthesis

Absolute configuration: (2R,3R)



C₄H₉NO₃


(2R,3S)-3-Amino-2-hydroxybutanoic acid

E.e. = 100%

[α]_D²³ = +21.6 (*c* = 1.1, H₂O)

Source of chirality: L-alanine and asymmetric synthesis

Absolute configuration: (2R,3S)




C₄H₉NO₃
(2S,3S)-3-Amino-2-hydroxybutanoic acid

E.e. = 100%

[α]_D²³ = -25.7 (*c* = 1.1, H₂O)

Source of chirality: L-alanine and asymmetric synthesis

Absolute configuration: (2S,3S)




C₇H₁₅NO₃
(2R,3S)-3-Amino-2-hydroxy-5-methylhexanoic acid

E.e. = 100%

[α]_D²³ = +28.7 (*c* = 0.3, AcOH)

Source of chirality: L-leucine and asymmetric synthesis

Absolute configuration: (2R,3S)




C₇H₁₅NO₃
(2S,3S)-3-Amino-2-hydroxy-5-methylhexanoic acid

E.e. = 100%

[α]_D²³ = -16.0 (*c* = 0.4, AcOH)

Source of chirality: L-leucine and asymmetric synthesis

Absolute configuration: (2S,3S)




C₁₀H₁₃NO₃
(2R,3S)-3-Amino-2-hydroxy-4-phenylbutanoic acid

E.e. = 100%

[α]_D²³ = -27.0 (*c* = 1.1, 1N HCl)

Source of chirality: L-phenylalanine and asymmetric synthesis

Absolute configuration: (2R,3S)



C₁₀H₁₃NO₃


(2S,3S)-3-Amino-2-hydroxy-4-phenylbutanoic acid

E.e. = 100%

[α]_D²³ = -5.1 (*c* = 0.9, 1N HCl)

Source of chirality: L-phenylalanine and asymmetric synthesis

Absolute configuration: (2S,3S)



C₉H₁₁NO₃


(2S,3R)-3-Amino-2-hydroxy-3-phenylpropanoic acid

E.e. = 100%

[α]_D²³ = +14.4 (*c* = 0.5, 6N HCl)

Source of chirality: D-phenylglycine and asymmetric synthesis

Absolute configuration: (2S,3R)



C₉H₁₁NO₃

(2R,3R)-3-Amino-2-hydroxy-3-phenylpropanoic acid

E.e. = 100%

[α]_D²³ = +3.6 (*c* = 0.5, 6N HCl)

Source of chirality: D-phenylglycine and asymmetric synthesis

Absolute configuration: (2R,3R)